Limbach Group adopts QuantaMatrix dRAST™ in routine clinical use
* QuantaMatrix's direct Rapid Antimicrobial Susceptibility Testing system (dRAST) improves optimal prescription of antibiotics by two days comparedto conventional methods * Following successful validation of dRAST platform in Europe at key reference laboratories, system now adopted for clinica...
2021-12-15 07:39
1529
QuantaMatrix to Debut on KOSDAQ on Wednesday (12/9) after raising $40.2mn in IPO, at $23.57
SEOUL, South Korea, Dec. 8, 2020 /PRNewswire/ -- QuantaMatrix (CEO Sunghoon Kwon ) is an in-vitro diagnostics company specializing in the discovery, development and commercialization of fully-integrated solutions within the sepsis value chain. QuantaMatrix successfully raised$40.2 million through ...
2020-12-08 20:30
5659
